Coronavirus Kits

Enjoy this 10 minute video to learn about two assays, offering Coronavirus clinical efficacy and vaccine potency testing on a single platform.

Kits Available

Coronavirus SeroAssay

Benefits

  • 2 hours from samples to result. 30 minutes hands on time
  • Multiplexed analysis of current and past endemic strains
  • 100% Clinical Specificity and and 98.5% Clinical Sensitivity
  • Compatible with recombinant, peptide, VLP and other advanced vaccine technologies.

Applications

  • Evaluate serological samples from preclinical and clinical studies
  • Screen immunological profile of study participants against all human coronaviruses
  • Quantify vaccine immunogenicity
  • Confirm cross protection against 7 different coronaviruses
  • Research population level seroprevalence

Coronavirus Spike Protien Assay

Benefits

  • 3 hours from samples to result. 30 minutes hands on time
  • Analysis of vaccine binding to ACE2 protein
  • Lower limit of detection is <15 ng/mL
  • Compatible with recombinant, subunit, VLP, and other advanced vaccine technologies

Applications

  • Quantify antigen directly
  • Optimize manufacturing process steps
  • Control vaccine quality in release testing
  • Evaluate stability and ACE2 binding of vaccine
  • Charecterize vaccine samples
  • Monitor vaccine shelf life

Register to learn how Kentucky BioProcess and BioIVT take advantage of VaxArray’s quick results for their Coronavirus vaccine development and get a link to access the latest peer reviewed article on the VaxArray Assay’s clinical performance on 263 human serum samples

Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses

– Journal of Virological Methods, Volume 291, May 2021, 114111

Abstract
Rapid, sensitive, and precise multiplexed assays for serological analysis during candidate COVID-19 vaccine development would streamline clinical trials. The VaxArray Coronavirus (CoV) SeroAssay quantifies IgG antibody binding to 9 pandemic, potentially pandemic, and endemic human CoV spike antigens in 2 h with automated results analysis. IgG antibodies in serum bind to the CoV spike protein capture antigens printed in a microarray format and are labeled with a fluorescent anti-species IgG secondary label. The assay demonstrated excellent lower limits of quantification ranging from 0.3 to 2.0 ng/mL and linear dynamic ranges of 76 to 911-fold. Average precision of 11 % CV and accuracy (% recovery) of 92.5 % over all capture antigens were achieved over 216 replicates representing 3 days and 3 microarray lots. Clinical performance on 263 human serum samples (132 SARS-CoV-2 negatives and 131 positives based on donor-matched RT-PCR and/or date of collection) produced 98.5 % PPA and 100 % NPA.

  • Register to learn how Kentucky BioProcess and BioIVT take advantage of VaxArray’s quick results for their Coronavirus vaccine development.

  • This field is for validation purposes and should be left unchanged.